Publications

Biochemical pharmacology

DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin.

15-01-2003

The Biochemical journal

Ceramide: second messenger or modulator of membrane structure and dynamics?

15-01-2003

Journal of immunotherapy (Hagerstown, Md. : 1997)

CD8+ T cell tolerance and cancer immunotherapy.

07-01-2003

The Journal of biological chemistry

Rac activation by lysophosphatidic acid LPA1 receptors through the guanine nucleotide exchange factor Tiam1.

03-01-2003

Anti-cancer drugs

Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma.

01-01-2003

Trends in biotechnology

Knockdown stands up.

01-01-2003

Immunity

Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I.

01-01-2003

Molecular and cellular biology

Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1.

01-01-2003

Molecular microbiology

The expression level determines the surface distribution of the transferrin receptor in Trypanosoma brucei.

01-01-2003

The Journal of cell biology

The fibronectin-binding integrins alpha5beta1 and alphavbeta3 differentially modulate RhoA-GTP loading, organization of cell matrix adhesions, and fibronectin fibrillogenesis.

23-12-2002

The oncologist

Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview.

20-12-2002

The New England journal of medicine

A gene-expression signature as a predictor of survival in breast cancer.

19-12-2002

JAMA

Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial.

18-12-2002

Current opinion in chemical biology

RNAi and related mechanisms and their potential use for therapy.

01-12-2002

Cancer chemotherapy and pharmacology

Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule.

01-12-2002

Molecular pharmacology

Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells.

01-12-2002

International journal of cancer

Submicromolar doses of alkyl-lysophospholipids induce rapid internalization, but not activation, of epidermal growth factor receptor and concomitant MAPK/ERK activation in A431 cells.

01-12-2002

International journal of radiation oncology, biology, physics

HIF-1A, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors.

01-12-2002

Clinical breast cancer

Cognitive dysfunction and chemotherapy: neuropsychological findings in perspective.

01-12-2002

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer.

01-12-2002

The Journal of urology

Controlling gene expression in the urothelium using transgenic mice with inducible bladder specific Cre-lox recombination.

01-12-2002

Current opinion in cell biology

Genome-wide histone modifications: gaining specificity by preventing promiscuity.

01-12-2002

Cancer treatment reviews

DNA-based drug interactions of cisplatin.

01-12-2002

Proceedings of the National Academy of Sciences of the United States of America

The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria.

26-11-2002

AIDS (London, England)

Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.

22-11-2002

Journal of pharmaceutical and biomedical analysis

Photostability profiles of the experimental antimetastatic ruthenium complex NAMI-A.

07-11-2002

International journal of pharmaceutics

Pharmaceutical development of a parenteral lyophilized formulation of the antimetastatic ruthenium complex NAMI-A.

06-11-2002

International journal of pharmaceutics

A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A.

06-11-2002

Bone marrow transplantation

Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy.

01-11-2002

Pharmacogenetics

Polymorphisms affecting function of the human organic cation transporter hOCT1 (SLC22A1): what are the consequences?

01-11-2002

Cancer research

Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.

01-11-2002

Molecular biology of the cell

Dynamics of the alpha6beta4 integrin in keratinocytes.

01-11-2002

Molecular and cellular biology

Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D.

01-11-2002

British journal of clinical pharmacology

Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).

01-11-2002

Anti-cancer drugs

E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer.

01-11-2002

The Journal of biological chemistry

TRAIL receptor and CD95 signal to mitochondria via FADD, caspase-8/10, Bid, and Bax but differentially regulate events downstream from truncated Bid.

25-10-2002

The Journal of biological chemistry

Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis.

18-10-2002

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.

01-10-2002

Anti-cancer drugs

Stability and compatibility of the investigational polymer-conjugated platinum anticancer agent AP 5280 in infusion systems and its hemolytic potential.

01-10-2002

Oncogene

Proviral activation of the tumor suppressor E2a contributes to T cell lymphomagenesis in EmuMyc transgenic mice.

26-09-2002

Journal of immunology (Baltimore, Md. : 1950)

Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas.

15-09-2002

British journal of cancer

A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin.

09-09-2002

Diabetic medicine : a journal of the British Diabetic Association

Longitudinal assessment of the development of diabetic polyneuropathy and associated risk factors.

01-09-2002

Annals of oncology : official journal of the European Society for Medical Oncology

Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients.

01-09-2002

Nature genetics

Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice.

01-09-2002

Anti-cancer drugs

An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients.

01-09-2002

Journal of mass spectrometry : JMS

Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry.

01-09-2002

Molecular biology of the cell

Agonist-induced PIP(2) hydrolysis inhibits cortical actin dynamics: regulation at a global but not at a micrometer scale.

01-09-2002

Cancer chemotherapy and pharmacology

Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.

01-09-2002

European journal of nuclear medicine and molecular imaging

Phase 1 study to identify tumour hypoxia in patients with head and neck cancer using technetium-99m BRU 59-21.

01-09-2002